Trials / Terminated
TerminatedNCT04504032
A Trial to Evaluate Safety and Efficacy of Rivaroxaban (COVID-19)
A Randomized, Controlled, Phase 2b Study to Evaluate Safety and Efficacy of Rivaroxaban (Xarelto®) for High Risk People With Mild COVID-19
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 497 (actual)
- Sponsor
- Gates Medical Research Institute · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess safety and clinical efficacy of rivaroxaban in people with mild Coronavirus Disease 2019 who are at increased risk of disease progression.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Rivaroxaban | Participants self-administered rivaroxaban, 10 milligrams (mg) (1 tablet) orally once daily for 21 days. |
| DRUG | Placebo | Participants self-administered rivaroxaban matching placebo orally once daily for 21 days. |
Timeline
- Start date
- 2020-09-02
- Primary completion
- 2021-03-10
- Completion
- 2021-03-29
- First posted
- 2020-08-07
- Last updated
- 2021-10-22
- Results posted
- 2021-10-22
Locations
20 sites across 2 countries: United States, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04504032. Inclusion in this directory is not an endorsement.